GEMP Gemphire Therapeutics
- 0.000
- 0.0000.00%
Gemphire Therapeutics News
Gemphire Therapeutics | 4: Statement of changes in beneficial ownership of securities
Gemphire Therapeutics | 3: Initial statement of beneficial ownership of securities
Gemphire Therapeutics | 8-K: Current report
Gemphire Therapeutics | 10-Q: Q2 2020 Earnings Report
Gemphire Therapeutics | 8-K: Current report
Gemphire Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Gemphire Therapeutics | S-8 POS: S-8 POS
Gemphire Therapeutics | UPLOAD: Others
Gemphire Therapeutics | UPLOAD: Others
Gemphire Therapeutics | CORRESP: CORRESP
Gemphire Therapeutics | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Gemphire Therapeutics | 25: Notification of the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Gemphire Therapeutics | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Gemphire Therapeutics | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Gemphire Therapeutics | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Gemphire Therapeutics | CB/A: Certain tender offers, business combinations and rights offerings, in which the subject company is a foreign private issuer of which less than 10% of its securities are held by U.S. persons (Amendment)
Gemphire Therapeutics | SC 13D/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities (Amendment)
Gemphire Therapeutics | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Gemphire Therapeutics | CB/A: Certain tender offers, business combinations and rights offerings, in which the subject company is a foreign private issuer of which less than 10% of its securities are held by U.S. persons (Amendment)
Gemphire Therapeutics | CB/A: Certain tender offers, business combinations and rights offerings, in which the subject company is a foreign private issuer of which less than 10% of its securities are held by U.S. persons (Amendment)
No Data